Navigation Links
InterMune to Release Third Quarter Financial Results on November 5
Date:10/29/2009

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2009 financial results on Thursday, November 5, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 37626791. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 37626791.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (ITMN-191) that entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline,
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release Second Quarter Financial Results on August 6
5. InterMune to Present at Goldman Sachs Healthcare Conference
6. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
7. InterMune to Release First Quarter Financial Results on April 30
8. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
9. InterMune to Present at Canaccord Adams Hepatitis C Conference
10. InterMune to Present at Citis 4th Annual Biotech Day
11. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  The full interim results will be ... GRS and IGF Society, being held October 15-18, ...
(Date:9/15/2014)... NYHeat drives classical phase transitionsthink solid, liquid, ... when the temperature drops. If phase transitions ... quantum mechanics reigns, subtle fluctuations can dramatically ... the U.S. Department of Energy,s Brookhaven National ... this frigid landscape of absolute zero to ...
(Date:9/15/2014)... University have developed a technique for controlling the surface ... opening the door to a new generation of reconfigurable ... on the fact that the oxide "skin" of the ... acts as a surfactant, lowering the surface tension between ... used a liquid metal alloy of gallium and indium. ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Researchers control surface tension to manipulate liquid metals 2
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Biotech and pharma companies,are increasingly utilizing novel ... early in the development cycle to avoid ... and,Biotechnology News (GEN) ( http://www.genengnews.com/ ). By ... early, pharma also has the opportunity to ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
Cached Biology Technology:MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
(Date:9/16/2014)... Schizophrenia is associated with increased rates and intensity of ... that the relationship between schizophrenia and smoking stems, in ... to self-medicate symptoms and cognitive impairment associated with the ... issue of Biological Psychiatry , sheds light on ... nicotine receptors in the brain was lower in schizophrenia ...
(Date:9/16/2014)... Proteins are responsible for practically all vital functions ... reactions, forward signals, transport particular substances and control ... that proteins do not function independently of each ... you examine the protein networks, you find many ... Falter-Braun from TUM,s Chair of Plant Systems Biology. ...
Breaking Biology News(10 mins):New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2
... The Society of Interventional Radiology Foundation,s Discovery Campaign, ... invasive medicine into new areas of discovery, announced ... a manufacturer of medical devices, pharmaceuticals and medical ... and is a "Visionary" level supporter. ...
... In the waters off the North Carolina coast, historically-significant ... seafloor, a testament to a relatively unknown chapter in ... shipwrecks are not only important for their cultural value, ... fishes, invertebrates and algal species. Additionally, due to their ...
... by two teams of Army scientists and collaborators has identified ... virus infection. The findings, published online today in separate studies ... for combating one of the world,s most deadly viruses. ... high as 90 percent in humans. The virus is of ...
Cached Biology News:Single protein, key to ebola virus infection, could aid in drug design 2
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
Biology Products: